http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
서울의 Penicillinase Producing Neisseria gonorrhoeae 발생빈도(1998)
김재홍,김준호,반재용,이정우,황성주,정준규,정성태,강진문,조흔정,홍창의,정혜신,이한승,김이선,이봉길,이종호,선영우,한기덕,윤성필,이성훈,안종성,박석범,문승현,조항래,김형섭,류지호,황재영,박준홍,손상욱 한양대학교 의과대학 2001 한양의대 학술지 Vol.21 No.1
In recent years, gonorrhea has been pandemic and remains one of the most common STDs in the world, especially in developing countries. For the detection of a more effective therapeutic regimen and assessing the prevalence of Penicillinase Producing Neisseria gonorrhoeae(PPNG), we have been trying to study the patients who have visited the Venereal Disease Clinic of Choong-Ku Public Health Center in Seoul since 1980 by menas of the chromogenic cephalosporin method. In 1998, 93 strians of N. genorrhoeae were isolated, among which 60(64.5%) were PPNG. The prevalence of PPNG in Seoul, which had been decreased to 39% in 1996 after a peak of 74.3% in 1993, is increased to 64.5% in 1998.
Ji Hyun Yoon,Cheong Soo Park,Ji Young Seo,최윤선,안영민 대한소아청소년과학회 2011 Clinical and Experimental Pediatrics (CEP) Vol.54 No.7
Purpose: To evaluate the clinical characteristics of vitamin D deficiency and its association with iron deficiency anemia (IDA). Methods: A total of 171 children aged less than two years underwent 25-hydroxyvitamin D_3 tests between January 2007 and July 2009. The study was classified into two groups: normal and vitamin D insufficiency, by their vitamin 25-hydroxyvitamin D3 levels. Results: In total, 120 children were in the normal group (mean age,body weight and heights 12.5±7.0, 9.3±0.9 kg and 76.8±1.1 cm), and 51 children in the vitamin D insufficiency group (9.9±5.4 months,9.0±0.9 kg and 75.1±0.9 cm). Vitamin D insufficiency was most commonly diagnosed in the spring (44%). The proportion of complete breast-feeding was higher in the insufficiency (92%), and 25.5% of the children in the deficient group also experienced IDA compared that 12% of normal group. Ten children in the insufficiency group experienced bony changes. Six children received calcitriol medication in the normal group, in whom the mean vitamin 25-hydroxyvitamin D3level increased from 39.6±14.6 ng/mL (pre-medication) to 41.8±17.2ng/mL (post-medication), and 13 in the insufficiency group, in whom the mean vitamin 25-hydroxyvitamin D3 increased from 20.7±7.0 ng/mL to a mean post-treatment level of 43.7±23.8 ng/mL. Conclusion: This study demonstrated that approximately 30% of children aged ≤2 years experienced vitamin D insufficiency associated with subclinical rickets. Many children also experienced concurrent IDA. Guidelines for vitamin D supplement in such children must therefore be established.
( Ji Yoon Cheong ),( Tae Wook Kong ),( Joo Hyuk Son ),( Je Hwan Won ),( Jeong In Yang ),( Haeng Soo Kim ) 대한산부인과학회 2014 Obstetrics & Gynecology Science Vol.57 No.1
Objective The aim of this study was to evaluate indications, efficacy, and complications associated with pelvic arterial embolization (PAE) for postpartum hemorrhage (PPH). Methods We retrospectively reviewed the medical records of 117 consecutive patients who underwent PAE for PPH between January 2006 and June 2013. Results In our single-center study, 117 women underwent PAE to control PPH refractory to conservative management including uterine massage, use of uterotonic agents, surgical repair of genital tract lacerations, and removal of retained placental tissues. Among 117 patients, 69 had a vaginal delivery and 48 had a Cesarean section. The major indication for embolization was uterine atony (54.7%). Other causes were low genital tract lacerations (21.4%) and abnormal placentation (14.5%). The procedure showed a clinical success rate of 88.0% with 14 cases of PAE failure; there were 4 hemostatic hysterectomies and 10 re-embolizations. On univariate analysis, PAE failure was associated with overt disseminated intravascular coagulation (P = 0.009), transfusion of more than 10 red blood cell units (RBCUs, P = 0.002) and embolization of both uterine and ovarian arteries (P = 0.003). Multivariate analysis showed that PAE failure was only associated with transfusions of more than 10 RBCUs (odds ratio, 8.011; 95% confidence interval, 1.531?41.912; P = 0.014) and embolization of both uterine and ovarian arteries (odds ratio, 20.472; 95% confidence interval, 2.715?154.365; P = 0.003), which were not predictive factors, but rather, were the results of longer time for PAE. Three patients showed uterine necrosis and underwent hysterectomy. Conclusion PAE showed high success rates, mostly without procedure-related complications. Thus, it is a safe and effective adjunct or alternative to hemostatic hysterectomy, when primary management fails to control PPH.
( Ji Yoon Cheong ),( Tae Wook Kong ),( Je Hwan Won ),( Jeong In Yang ),( Haeng Soo Kim ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.99 No.-
The aim of this study was to evaluate indications, efficacy, and complications associated with pelvic arterial embolization (PAE) for postpartum hemorrhage (PPH). We retrospectively reviewed the medical records of 117 consecutive patients who underwent PAE for PPH between January 2006 and June 2013. In our single-center study, 117 women underwent PAE to control PPH refractory to conservative managements including uterine massage, use of uterotonic agents, surgical repair of genital tract lacerations, and removal of retained placental tissues. Among 117 patients, 69 had a vaginal delivery and 48 had a cesarean section. The major indication for embolization was uterine atony (54.7%). Other causes were low genital tract lacerations (21.4%) and abnormal placentation (14.5%). The procedure showed a clinical success rate of 88.0% with fourteen cases of pelvic arterial embolization failure. There were four hemostatic hysterectomies and ten re-embolizations. On univariate analysis, PAE failure was associated with overt DIC (p=0.009), more than 10 RBCUs (red blood cell unit) transfused (p=0.002) and embolization of both uterine and ovarian arteries (p=0.003). Multivariate analysis showed that PAE failure was only associated with more than 10 RBCUs transfused (odds ratio, 8.011; 95% confidence interval 1.531-41.912; p=0.014) and embolization of both uterine and ovarian arteries (odds ratio, 20.472; 95% confidence interval 2.715-154.365; p=0.003), which were not predictive factors, but the results of longer time for PAE. Three patients showed uterine necrosis which underwent hysterectomy. PAE showed high success rates, mostly without procedure-related complications. Thus, it is a safe and effective adjunct or alternative to hemostatic hysterectomy, when primary managements fail to control postpartum hemorrhage.
Pelvic arterial embolization for postpartum hemorrhage: A retrospective review of 75 cases
( Ji Yoon Cheong ),( Yoo Jung Shin ),( Tae Wook Kong ),( Ji Heum Pa다 ),( Suk Joon Chang ),( Mi Ran Kim ),( Kyung Joo Hwang ),( Jeong In Yang ),( Ki Hong Chang ),( Haeng Soo Kim ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
The aim of this study was to evaluate indications, efficacy, and complications associated with pelvic arterial embolization for postpartum hemorrhage. We retrospectively reviewed the medical records of seventy-five consecutive patients who underwent pelvic arterial embolization for postpartum hemorrhage between January 2006 and March 2012. In our single-center study, 75 women underwent pelvic arterial embolization to control postpartum hemorrhage refractory to conservative managements, such as the use of the uterotonic agents, manual exploration of the uterus, suturing possible lacerations, and fundal massages. Among the 75 patients, 44 had a vaginal delivery and 31 had a Cesarean section. The major indication for embolization was uterine atony (66.7%). Other causes are abnormal placentation (17.3%) and low genital tract lacerations (10.7%). The procedure showed a clinical success rate of 96.0% with three cases of pelvic arterial embolization failure in which hemostatic hysterectomy was performed. Three patient (4.0%) presented complications related to the procedure, such as uterine necrosis and endometritis. Pelvic arterial embolization showed a high success rate, mostly without procedure related complications. Thus, it is a safe and effective adjunct or alternative to hemostatic hysterectomy, when primary managements fail to control postpartum hemorrhage.
Yoon, Ji-Hyun,Park, Cheong-Soo,Seo, Ji-Young,Choi, Yun-Sun,Ahn, Young-Min The Korean Pediatric Society 2011 Clinical and Experimental Pediatrics (CEP) Vol.54 No.7
Purpose: To evaluate the clinical characteristics of vitamin D deficiency and its association with iron deficiency anemia (IDA). Methods: A total of 171 children aged less than two years underwent 25-hydroxyvitamin $D_3$ tests between January 2007 and July 2009. The study was classified into two groups: normal and vitamin D insufficiency, by their vitamin 25-hydroxyvitamin $D_3$ levels. Results: In total, 120 children were in the normal group (mean age, body weight and heights $12.5{\pm}7.0$, $9.3{\pm}0.9$ kg and $76.8{\pm}1.1$ cm), and 51 children in the vitamin D insufficiency group ($9.9{\pm}5.4$ months, $9.0{\pm}0.9$ kg and $75.1{\pm}0.9$ cm). Vitamin D insufficiency was most commonly diagnosed in the spring (44%). The proportion of complete breast-feeding was higher in the insufficiency (92%), and 25.5% of the children in the deficient group also experienced IDA compared that 12% of normal group. Ten children in the insufficiency group experienced bony changes. Six children received calcitriol medication in the normal group, in whom the mean vitamin 25-hydroxyvitamin $D_3$ level increased from $39.6{\pm}14.6$ ng/mL (pre-medication) to $41.8{\pm}17.2$ ng/mL (post-medication), and 13 in the insufficiency group, in whom the mean vitamin 25-hydroxyvitamin $D_3$ increased from $20.7{\pm}7.0$ ng/mL to a mean post-treatment level of $43.7{\pm}23.8$ ng/mL. Conclusion: This study demonstrated that approximately 30% of children aged ${\leq}2$ years experienced vitamin D insufficiency associated with subclinical rickets. Many children also experienced concurrent IDA. Guidelines for vitamin D supplement in such children must therefore be established.
Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity
Beom, Ji Yoon,Jung, Jin A,Lee, Kyung-Tae,Hwangbo, Areum,Song, Myoung Chong,Lee, Yeonseon,Lee, Soo Jung,Oh, Ji Hoon,Ha, Sang-Jun,Nam, Sang-Jip,Cheong, Eunji,Bahn, Yong-Sun,Yoon, Yeo Joon American Chemical Society and American Society of 2019 Journal of natural products Vol.82 No.8
<P>A reduction in the strong immunosuppressive activity of FK506 (<B>1</B>) is essential for developing this compound as an antifungal agent. Seven new FK506 analogues modified at both the FK506-binding protein 12- and the calcineurin-binding regions were biosynthesized. 9-DeoxoFK520 (<B>7</B>) exhibited a >900-fold reduction in the <I>in vitro</I> immunosuppressive activity but maintained significant antifungal activity, indicating that the C-9 and C-21 positions are critical for separation of immunosuppressive and antifungal activities. <B>7</B> exhibited robust synergistic antifungal activity with fluconazole. FK506 (<B>1</B>) is a 23-membered macrolide produced by several <I>Streptomyces</I> species and is used as an immunosuppressive drug to prevent the rejection of transplanted organs. FK506 has also exhibited antifungal, neuroprotective, and neuroregenerative activities. In humans, FK506 binds to FK506-binding protein (FKBP) 12, and the resulting FKBP12-FK506 complex interacts with a Ca<SUP>2+</SUP>-calmodulin-dependent phosphatase, calcineurin (CaN). Inactivation of CaN by forming the FKBP12-FK506-CaN ternary complex prevents the activation of nuclear factor of activated T cells (NF-AT), inhibiting the production of interleukin-2 and subsequent T-cell proliferation. This CaN signaling pathway also plays a critical role in the growth and pathogenesis of major fungal pathogens such as <I>Cryptococcus neoformans</I>, <I>Candida albicans</I>, and <I>Aspergillus fumigatus</I>. Therefore, the synthesis of FK506 analogues that can discriminate human FKBP12/CaN from its fungal counterparts may separate antifungal activity from the immunosuppressive activity, thereby allowing the development of a novel antifungal agent.</P> [FIG OMISSION]</BR>
Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea
Yoon Jin Gu,Sohn Jang Wook,Choi Won Suk,Wie Seong-Heon,Lee Jacob,Lee Jin-Soo,Jeong Hye Won,Eom Joong Sik,Seong Hye,Nham Eliel,Choi Yu Jung,Noh Ji Yun,Song Joon Young,Cheong Hee Jin,Kim Woo Joo 대한의학회 2024 Journal of Korean medical science Vol.39 No.3
Background: Bivalent booster mRNA vaccines containing the omicron-variant strains have been introduced worldwide in the autumn of 2022. Nevertheless, the omicron subvariants evoked another large coronavirus disease 2019 (COVID-19) pandemic wave in late 2022 and early 2023. Methods: A retrospective, test-negative, case-control study was conducted to estimate the vaccine effectiveness (VE) of bivalent COVID-19 vaccines in 8 university hospitals between January and February 2023. The case and control groups were divided based on nasopharyngeal COVID-19 real-time polymerase chain reaction results and matched based on age, sex, hospital, and date (week) of the test performed. The VE of the BA.1- or BA.4/BA.5- based mRNA vaccines were estimated. VE was calculated using the 1−adjusted odds ratio from multivariable logistic regression. Results: In total, 949 patients and 947 controls were enrolled in this study. VE for the BA.4/ BA.5-based bivalent mRNA vaccine was 43% (95% confidence interval [CI], 17, 61%). In subgroup analysis based on age and underlying medical conditions, BA.4/BA.5-based bivalent mRNA vaccine was effective against old adults aged ≥ 65-years (VE, 55%; 95% CI, 23, 73%) and individuals with comorbidities (VE, 54%; 95% CI, 23, 73%). In comparison, the BA.1-based bivalent mRNA vaccine did not demonstrate statistically significant effectiveness (VE, 25%; 95% CI, −8, 49%). Conclusion: The BA.4/BA.5-based bivalent mRNA booster vaccine provided significant protection against COVID-19 in the Korean adults, especially in the older adults aged ≥ 65 years and in individuals with underlying medical conditions.